Share this video  

ESMO 2020 | IMvigor130: patient-reported outcomes by the addition of atezolizumab to PBC in mUC

Aris Bamias, MD, PhD, National and Kapodistrian University of Athens, Athens, Greece, gives a summary of his presentation on the IMvigor130 Phase III study (NCT02807636) at the ESMO 2020 Education Weekend. Dr Bamias reports that the ongoing study, which compares the efficacy of atezolizumab as a monotherapy and in combination with platinum-based chemotherapy (PBC) for the treatment of untreated locally advanced metastatic urothelial carcinoma (mUC), has so far shown significant prolongation of progression-free survival (PFS) by addition of atezolizumab to PBC. He also reports that analysis of patient-reported outcomes has found no detrimental effect of either therapy, suggesting that both therapies are well-tolerated in this patient population. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).